Form 4: Ionis Pharmaceuticals Director Loscalzo Reports Stock Vesting
SEC Form 4 Filing
Director Joseph Loscalzo reports the vesting of restricted stock units into Ionis Pharmaceuticals common stock.
Summary
- On July 15, 2024, Director Joseph Loscalzo acquired 4,677 shares of Ionis Pharmaceuticals common stock due to the vesting of restricted stock units.
- The shares were acquired at a price of $0.00 per share.
- Following the transaction, Loscalzo directly owns 45,759 shares of Ionis Pharmaceuticals common stock.
- Loscalzo also owns 4,079 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral event related to standard executive compensation practices.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The vesting of stock options and restricted stock units can have a dilutive effect on existing shareholders, but is also intended to align management's interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/15/2024 | Date of transaction: vesting of restricted stock units and acquisition of common stock. |
| 07/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.